Scientific work

Uzm. Dr. Ece Ulukal Karancı

19 publications. The source of the information is stated next to each publication.

Back to profile

  1. The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-44980-w PMID 41888201 Open-access full textSource: OpenAlex

  2. The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor–positive, HER-2–negative metastatic breast cancer: A real-world, multicenter, retrospective study.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.e24144 Source: OpenAlex

  3. The Prognostic Significance of the NOLUS Score in Patients with Metastatic Breast Cancer Receiving CDK 4/6 Inhibitor Therapy

    Acta Medica Alanya, 2026

    DOI 10.30565/medalanya.1842660 Open-access full textSource: ORCID

  4. Prognostic impact of pathological complete response in hormone receptor–positive/HER2-negative breast cancer treated with neoadjuvant chemotherapy: a multicenter cohort study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-63952-8 Open-access full textSource: ORCID

  5. Does Social Media Use Associate with Vasomotor, Sexual, and Musculoskeletal Symptoms in Breast Cancer Survivors Receiving Endocrine Therapy?

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15124726 PMID 42355893 Open-access full textSource: ORCID

  6. Prediction of pathological complete response after neoadjuvant treatment in triple negative breast cancer: a single center experience

    Pamukkale Medical Journal, 2026

    DOI 10.31362/patd.1707522 Open-access full textSource: ORCID

  7. Prognostic Impact of Cetuximab-Related Hypomagnesemia and Hypokalemia in RAS/RAF Wild-Type Colorectal Cancer: A Multicenter Study

    Cancer Management and Research, 2026

    DOI 10.2147/cmar.s570548 PMID 41930183 Open-access full textSource: OpenAlex

  8. Abstract PS1-11-04: Her2-low expression is associated with inferior progression-free survival in hr-positive metastatic breast cancer treated with CDK4/6 inhibitors

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps1-11-04 Source: OpenAlex

  9. 560eP Early neutropenia does not predict survival in older patients treated with CDK4/6 inhibitors: A real-world analysis

    ESMO Open, 2026

    DOI 10.1016/j.esmoop.2026.107581 Open-access full textSource: OpenAlex

  10. Effect of "watch and wait" on fear of recurrence in rectal cancer: A multicenter cross-sectional study.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.12116 Open-access full textSource: OpenAlex

  11. Possible Ribociclib-Associated Focal Nodular Hyperplasia–Like Lesion Mimicking Liver Metastasis in a Chemotherapy-Naïve Patient: First Case Report

    Cancer Research and Treatment, 2026

    DOI 10.4143/crt.2026.0178 PMID 42526851 Open-access full textSource: OpenAlex

  12. Prognostic impact of primary tumor location in patients undergoing curative resection for colon cancer

    The Atlantic Journal of Medical Science and Research, 2026

    DOI 10.5455/atjmed.2026.02.015 Open-access full textSource: OpenAlex

  13. Prognostic Value of Systemic Inflammation Markers and Clinical Factors in Grade 4 Diffuse Glioma: A Multicenter Retrospective Real-World Study

    Cancers, 2026

    DOI 10.3390/cancers18193192 PMID 42882885 Open-access full textSource: OpenAlex

  14. The Gustave Roussy immune score as a novel biomarker for predicting survival in patients with isocitrate dehydrogenase wild-type glioblastoma treated with the Stupp protocol

    Expert Review of Anticancer Therapy, 2025

    DOI 10.1080/14737140.2025.2555467 PMID 40883857 1 citation (Europe PMC) Source: OpenAlex

  15. 2836P The effect of ribociclib dose reduction on progression-free survival in hormone receptor positive and HER-2 negative metastatic breast cancer: A multicenter study

    Annals of Oncology, 2025

    DOI 10.1016/j.annonc.2025.08.3448 Open-access full textSource: OpenAlex

  16. Symptom Reporting Behaviors, Symptom Burden, and Quality of Life in Patients with Hormone Receptor–Positive Breast Cancer Undergoing Adjuvant Endocrine Therapy

    Current Oncology, 2025

    DOI 10.3390/curroncol32110599 PMID 41294660 1 citation (Europe PMC) Open-access full textSource: ORCID

  17. The correlation of vitamin D level with the disease etiology and disease level in patients with chronic liver disease The correlation of vitamin D level with the disease etiology in with chronic liver disease

    Annals of Clinical and Analytical Medicine, 2021

    DOI 10.4328/acam.20721 Open-access full textSource: ORCID

  18. NSAID, antiaggregant, and/or anticoagulant-related upper gastrointestinal bleeding: Is there any change in prophylaxis rate after a 10-year period?

    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2019

    DOI 10.5152/tjg.2019.19057 PMID 31199288 13 citations (Europe PMC) Open-access full textSource: ORCID

  19. A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study

    Supportive Care in Cancer, 2015

    DOI 10.1007/s00520-014-2531-6 PMID 25433439 16 citations (Europe PMC) Source: ORCID